

# Test and link to care: How do we measure our success?

Dr Valerie Delpech HIV & STI Department, National Infection Service Public Health England



# Early diagnosis and treatment safes lives and prevents onward transmission

#### Successful implementation **Public Health**

Testing strategies should be delivered using a human rights approach - voluntary, confidential, consent, linkage to care and treatment following diagnosis, and access to prevention services for those who are negative.

#### FACTS criteria

England

Feasibility,

Acceptability,

Cost-effectiveness,

Target population reached and

Sustainability of the intervention with regular feedback to key stakeholders. – ECDC testing guidelines



# Scaling up testing and link to care and treatment





Help improve the lives



### **Community engagement**

- Stigma and discrimination remains major barrier to testing, link and retention in care and prevention efforts
- Need greater engagement of affected communities at every level
- Tailored messages for individuals recognising diverse nature of community
- Support peer-led initiatives and outreach programs
- Sustained funding for NGOs
- Provision of integrated and welcoming, non judging services in partnership with NGOs





## Tackling barriers Innovate, recycle and share




Laws or policies that authorise/prevent types of HIV (



Laws and policies	Authorise	Prevent	N/A laws or policies
Community-based testing delivered by trained medical staff	36	0	10
Community-based testing delivered by non-medical staff (e.g. trained lay people)	15	17	14
Home-sampling kits	8	7	30
Self-testing kits	7	9	30


#### THE PEOPLE LIVING WITH HIV STIGMA SURVEY UK 2015

Reported experiences of stigma and discrimination in the last 12 months in the health care setting, 2015




### Measuring success: Know your epidemiology

- Undiagnosed and late diagnosed
- AIDS and AIDS deaths
- New diagnoses / incidence
- Testing patterns
- Link to care, Treatment uptake
- ALL by most at risk groups
- 90 90 90 is not enough
- Test frequently and reduce time to test and treat




#### Current global estimates for the care cascade Levi et al 2016\*




#### \* Based on 69/196 countries – 32 complete, 37 partial data

Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Glob Health 2016;

# How are countries in Europe performing against the 90-90-90 treatment targets? N=16




ECDC. Thematic report: HIV continuum of care. Monitoring implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2014 progress report. Stockholm: ECDC; 2015.



#### Adjusted\* number of adults with diagnosed HIV infection starting treatment, by CD4 count at ART initiation: UK

Public Health

England



\*Adjusted for missing/inconsistent CD4 count at diagnosis, 24% overall




#### HIV Clinical Dashboard indicators England

Indicator	Specification	2012	2014
Late diagnosis	To monitor timeliness of diagnosis <i>CD4 cell count &lt;350 cells/mm<sup>3</sup> within 3</i> <i>months of diagnosis</i>	47%	40%
Link to care	To monitor prompt integration into care following HIV diagnosis: CD4 cell count taken within 1 month of diagnosis	88%	93%
Retention in care - new patients	To monitor the retention in care among newly- diagnosed adults: <i>New diagnoses seen for care in the next</i> <i>survey year</i>	86%	89%
Retention in care - all patients	To monitor the retention in care among adults seen for care in the last 12 months Adults seen for HIV care and also seen in the net survey year	96%	95%
Viral load suppression	To monitor the effectiveness of ART after initiating treatment Viral load <200 copies/ml at 12 months of starting ART (window period 3 – 15 months)	92%	95%
CD4 response	To monitor immune status of adults regardless of treatment status CD4 cell count ≥350 cells/mm <sup>3</sup> after at least 12 months in HIV care	83%	86%



Satisfaction with Care – HIV specialist and GP

#### "Overall, how would you rate your GP/HIV specialist services?"





New agreed questions included in the national HIV and STI datasets

#### **Q1 Gender identity**

Which of the following options best describes how you think of yourself?

Female (including trans woman) Male (including trans man) Non-binary In another way\* Not stated (PERSON asked but declined to provide a response) Not known (not recorded)

#### **Q2 Trans status**

Is your gender identity the same as the gender you were given at birth?

Yes

No

Not stated (PERSON asked but declined to provide a response) Not known (not recorded)

- Coded as "Other" in the NHS data dictionary
- Please not that a text field may be added to this field to provide a description of 'in another way'
- However note there are no text field in the HARS dataset




Protecting and improving the nation's health

# Combination approach to prevention



#### New HIV diagnoses in STI clinics in the UK, the beginning of a downturn in gay/bisexual men?



### Situation Jan 2017

- PHE Ongoing investigation
- High rise in number of HIV tests among MSM particular clinics



- Especially high rise in testing and sexual health screens among repeat testers
- Associated with downturn in some STIs and HIV in recent months, decreased late diagnoses
- Improvements in early ART and decrease in the number of men with unsuppressed viral load
- Prep Use increasing
- Most likely decrease in incidence due combination of interventions



### 4<sup>th</sup> decade of the HIV epidemic

- We have the tools & know what to do scientific knowledge
- Need to better contextualise knowledge for communities
- Innovate and re-novate
- Expect constant change and refinement and big step changes
- Advocate for generics and prevention funding
- Tackle legal barriers and/or creatively circumvent them
- Models can only do so much timely accurate information for setting policy and monitoring efforts is crucial
- Public health working in partnership with health professionals and community



John Walter, 2015

# Thank you & Acknowledgements

Teymur Noori, Anastasia Pharris and Andrew Amato, ECDC Cary James – Terence Higgins Trust, HIV Prevention England Andrew Phillips and colleagues at UCL Andrew Hill and colleagues at Imperial

Colleagues PHE: Anthony Nardone, Gwenda Hughes, Noel Gill, Kathy Lowndes, Owen Brigstock-Barron, Luis Guerra, Daniella De Angelis, Anne Presanis, Stefano Conti

HARS team— Alison Brown, Meaghan Kall, Sara Croxford, Sandra Okala, Peter Kirwan, Cuong Chau, Matthew Hibbert, Jameel, Amrita Nick Cooper, Rajani Ragu, Janice Morgan, Adamma Agazhui, Zheng Yin